Evaluating the Efficacy of a New Medication for Hidradenitis Suppurativa

Purpose

The purpose of the study is to evaluate if a new investigational medication, Bimekizumab, works for patients with hidradenitis suppurativa (HS). Earlier studies of Bimekizumab have shown that the medication is effective in patients with HS. This study compares the effects of Bimekizumab to an FDA-approved medicine, Adalimumab, and a placebo (no active medicine). To evaluate how well Bimekiumab works, we will perform a range of assessments to see how the severity of HS can decrease and quality of life could be improved.

Keywords: dermatology, hidradenitis suppurativa

Study Sites

Keck School of Medicine, Los Angeles 90033

 
  • Men & Women
Age icon
18-70
 

We're sorry, but this trial is no longer enrolling volunteers.

What's involved?

Study length

  • 30 weeks

Number of visits

  • Up to 12 visits

Prescription

  • Bimekizumab OR Adalimumab OR placebo

Procedures

  • Skin biopsies (a sample of your skin)

Compensation

  • Compensation is available for the completion of each study visit.

Medical cost coverage

  • All study-related visits, tests, and study drug will be provided at no cost to the participant

Why participate?

Medical advances are impossible without volunteers.

Eligibility

Must have

  • Diagnosis of moderate to severe hidradenitis suppurativa
  • 18 years or older

Can't have

    There are no exclusion criteria

Study Team

Klzgupjvszojzdlowlmy
Principal Investigator
April W. Armstrong, MD MPH

For questions about this study, contact:

We respect your privacy!

All the information you give us is stored in a secure, password protected database. All the information that you choose to share will be kept private and confidential. Read University of Southern California's Privacy Policy here.